BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT ANNUAL SITC MEETING
Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will today present an updated clinical & translational analysis from its Phase II bemcentinib and pembrolizumab combination study (BGBC008) in advanced non-small cell lung cancer (NSCLC), at an oral presentation at the Society for Immunotherapy of Cancer (SITC) 35[th] Annual Meeting. The presentation will provide updated data from Cohort B of the study, assessing the safety and efficacy of bemcentinib in